Toll Free: 1-888-928-9744

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 56 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2016', provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview 6 Therapeutics Development 7 Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview 7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies 8 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies 12 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development 13 Baxalta Incorporated 13 CSL Limited 14 GeNeuro SA 15 Mitsubishi Tanabe Pharma Corporation 16 Pfizer Inc. 17 Teijin Pharma Limited 18 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 fingolimod hydrochloride - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 GL-2045 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 GNbAC-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 immune globulin (human) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 immune globulin (human) - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 immune globulin (human) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Recent Pipeline Updates 42 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects 50 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones 51 Featured News & Press Releases 51 Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 51 Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 51 Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 52 Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 52 May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 53 Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Baxalta Incorporated, H1 2016 13 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Limited, H1 2016 14 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H1 2016 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 16 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H1 2016 17 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Assessment by Combination Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics - Recent Pipeline Updates, H1 2016 42 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H1 2016 50


List of Figures
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify